Basilard BioTech's Celletto™ platform provides a mechanical approach to gene delivery that consistently achieves higher transfection, cell viability performance, and yields compared to prevailing viral delivery methods. Celletto™ is a superior solution for non-viral gene delivery, addressing the limitations of biological and ex-vivo gene delivery and scaling manufacturing cost-effectively. The platform offers greater scalability, safety, efficiency, and versatility than prevailing viral delivery methods, as well as lower cost and lead time. Celletto™ is also a superior platform for primary T cell engineering than both electroporation and the prevailing viral delivery methods.